AA Financial Advisors LLC Boosts Stake in AstraZeneca PLC (NASDAQ:AZN)

by · The Cerbat Gem

AA Financial Advisors LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,710 shares of the company’s stock after buying an additional 752 shares during the period. AA Financial Advisors LLC’s holdings in AstraZeneca were worth $601,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC boosted its holdings in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after acquiring an additional 133 shares during the last quarter. Bruce G. Allen Investments LLC lifted its position in AstraZeneca by 19.1% during the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after purchasing an additional 138 shares during the period. Carnegie Investment Counsel boosted its holdings in AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares during the period. Finally, Sunpointe LLC raised its stake in AstraZeneca by 4.5% during the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after buying an additional 147 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZN opened at $78.26 on Friday. The firm has a market cap of $242.65 billion, a P/E ratio of 37.81, a PEG ratio of 1.45 and a beta of 0.46. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a 50 day simple moving average of $81.13 and a two-hundred day simple moving average of $78.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69.

AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the prior year, the business posted $1.08 EPS. AstraZeneca’s revenue for the quarter was up 9.1% compared to the same quarter last year. Equities analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were issued a $0.49 dividend. The ex-dividend date was Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s dividend payout ratio is presently 47.34%.

Analysts Set New Price Targets

Several brokerages recently commented on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Finally, TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

Check Out Our Latest Stock Analysis on AZN

AstraZeneca Company Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).